Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

Better Artificial Intelligence Stock for 2026: C3.ai vs. SentinelOnefool.com
C3.ai is burning cash while restructuring its sales model. SentinelOne is profitable on free cash flow but trades at a steep valuation premium.
Via The Motley Fool · October 19, 2026
Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenantsmarketbeat.com
Kevin O'Leary expects 65% of announced data center projects to fail, making permitted, powered sites scarce. What that means for Bitzero, CoreWeave and IREN.
Via MarketBeat · October 19, 2026
Where Will Vertiv Stock Be in 1 Year?fool.com
The provider of data center cooling and power supply systems has a bright future.
Via The Motley Fool · October 19, 2026
Cliffs (CLF) Q3 2026 Earnings Call Transcriptfool.com
Record EBITDA on steel prices and cost discipline; 2027 guidance exceeds $4 billion.
Via The Motley Fool · October 19, 2026
Why AMD Stock Popped on Mondayfool.com
AMD's TAM just doubled -- and this analyst says it's a buy.
Via The Motley Fool · October 19, 2026
Netflix's Co-CEO Ted Sarandos Just Gave Investors Bad News Before Earningsfool.com
The company is laying off staff, and management hasn't been thrilled with its growth.
Via The Motley Fool · October 19, 2026
Is Nvidia Stock a Buy After Its Historic $235 Billion Buyback?fool.com
Nvidia's new buyback puts its cash generation, valuation, and per-share economics under the microscope. Here's what investors should watch as the program unfolds.
Via The Motley Fool · October 19, 2026
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Resultsmarketbeat.com
Veradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss. The randomized, double-blind, placebo-controlled study enrolled 536
Via MarketBeat · October 19, 2026
What Fifth Third Bancorp (FITB) Said on Its Q3 Earnings Callmarketbeat.com
Fifth Third Bancorp (NASDAQ:FITB) reported third-quarter earnings per share of $0.90, or $1.13 excluding certain items, as the regional bank completed the technical conversion tied to its acquisition of Comerica and continued to post loan and deposit growth. Chairman, CEO and President Tim Spence s
Via MarketBeat · October 19, 2026
Better Emerging Markets ETF: Schwab's SCHE vs. Vanguard's VWOfool.com
Both charge identical 0.06% fees, but Schwab delivers a higher 2.7% dividend yield while Vanguard provides nearly 6,000 holdings for broader diversification.
Via The Motley Fool · October 19, 2026
Why Palantir Technologies Stock Rallied Todayfool.com
The data mining and AI specialist announced another expansive partnership.
Via The Motley Fool · October 19, 2026
Arista Networks Is Heading for a Big Test on Nov. 3. Here's What Could Send the Stock Soaring.fool.com
Forget third-quarter earnings. I'm more interested in management guidance for the fourth quarter.
Via The Motley Fool · October 19, 2026
Insider Buying Is Rising at These 3 Regional Banks, But the Details Matterinsidertrades.com
Insiders and institutions are buying select small-cap bank stocks like Five Star Bancorp, Mid Penn Bancorp, and Riverview Bancorp, citing dividend growth, margin trends, and acquisition catalysts.
Via MarketBeat · October 19, 2026
Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?marketbeat.com
Alcoa beat Q3 2026 earnings estimates with $1.82 adjusted EPS, as its Pinjarra refinery stabilized and aluminum margins stayed near record levels despite the stock trading near its yearly lows.
Via MarketBeat · October 19, 2026
Stock Market Midday, Oct. 19: Tech Stocks Rebound as AI Confidence Returnsfool.com
Nasdaq climbs, lifted by semiconductor and cloud infrastructure plays ahead of mega-cap earnings, today, Oct. 19, 2026.
Via The Motley Fool · October 19, 2026
Magnificent Seven Are Losing Their Earnings Lusterinvestors.com
The Magnificent Seven are on track to increase earnings 33.2% in the third quarter. Micron Technology now has the largest S&P 500 earnings.
Via Investor's Business Daily · October 19, 2026
Rocket Lab Delays Neutron Again. Is the Stock in Trouble?fool.com
The company now projects that Neutron's inaugural launch will take place next year.
Via The Motley Fool · October 19, 2026
1 eVTOL Stock That Could Turn $5,000 Into $50,000 -- and the 1 Risk That Could Wipe It Outfool.com
In 2036, Joby Aviation could look like a totally different company.
Via The Motley Fool · October 19, 2026
Micron Technology Stock: Is It a No-Brainer Buy at Less Than $900?fool.com
The stock hasn't been trading this low since early August.
Via The Motley Fool · October 19, 2026
2 "Magnificent Seven" Stocks to Buy and Hold for the Rest of the Decadefool.com
Amazon and Alphabet are my two favorite "Magnificent Seven" stocks to own for the long term.
Via The Motley Fool · October 19, 2026
Why Cleveland-Cliffs Stock Popped Todayfool.com
Cleveland-Cliffs' adjusted EBITDA more than doubles versus Q2 on strong steel pricing.
Via The Motley Fool · October 19, 2026
Illinois Tool Works Faces Headwinds—2 Alternatives Stand Outmarketbeat.com
Illinois Tool Works faces short-cycle demand headwinds and price target cuts, while Watts Water Technologies and the Vanguard Industrials ETF offer alternative ways to play the industrials sector.
Via MarketBeat · October 19, 2026
1 Green Flag and 1 Red Flag for Bloom Energy Investorsfool.com
There's a lot to like about this hydrogen stock, but one factor may charge up investors to look elsewhere.
Via The Motley Fool · October 19, 2026
Is Eli Lilly Stock a Buy Right Now?fool.com
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.
Via The Motley Fool · October 19, 2026
Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmissionmarketbeat.com
Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company’s plan to resubmit a new drug application
Via MarketBeat · October 19, 2026